Preceding bortezomib administration for a certain period reduces the risk of lenalidomide‐induced skin rash - Sugi, Tomiyuki; Mita, Mitsuo; Yasu, Takeo; Kubo, Kana; Kushi, Ryota; Hanai, Homare; Ohara, Shin; Uchida, Tomoyuki; Inoue, Morihiro; Hagihara, Masao (Journal of Clinical Pharmacy and Therapeutics, 2022)
Keywords: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bortezomib; Bortezomib - adverse effects; Dexamethasone; Dexamethasone - therapeutic use; Exanthema; Exanthema - chemically induced; Exanthema - epidemiology; Exanthema - prevention & control; Humans; Immunotherapy; Inhibitor drugs; Investigations; Lenalidomide; Lenalidomide - adverse effects; Multiple Myeloma; Multiple Myeloma - drug therapy; Multivariate analysis; Patients; Retrospective Studies; Skin; skin rash; Targeted cancer therapy; skin rash; bortezomib; lenalidomide